Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG7800 in SMA (MOONFISH)
NCT02240355Phase 1Terminated
- Sponsor
- Roche
- Start
- Nov 2014
- Primary completion
- Jul 2015
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 9
01
Overview
Phase 1, randomised, double-blind trial of olezarsen in spinal muscular atrophy (SMA) (5 arms), sponsored by Roche. Primary endpoint: Incidence of adverse events at 20 weeks. Started Nov 2014; status: terminated.
02
Drugs
olezarsen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02240355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240355.